Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100B | P04271 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512906 | 0.88 | S100B (0.38) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL10346490 | 0.87 | S100B (0.54) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL150487 | 0.86 | ADRA2A (0.37) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL128645 | 0.84 | S100B (0.47) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL30612673 | 0.82 | NSD2 (0.42) | ALDH1A1MEN1KMT2AHPGDCYP2C9 | |
| SCHEMBL743428 | 0.82 | NSD2 (0.42) | ALDH1A1MEN1KMT2AHPGDCYP2C9 | |
| SCHEMBL151025 | 0.82 | NSD2 (0.42) | ALDH1A1MEN1KMT2AHPGDCYP2C9 | |
| SCHEMBL2430669 | 0.81 | S100B (0.54) | S100BALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL152875 | 0.81 | S100B (0.31) | S100BLMNASMN1; SMN2 | |
| SCHEMBL972851 | 0.78 | S100B (0.47) | S100BALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430007-B1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LAB LTD (SG) | 2014-02-12 | — | — | EP | disclosed |
| EP-2547668-A1 | TOLUIDINE BLUE DERIVATIVES AS PHOTOSENSITISING COMPOUNDS | Pharmalucia Ltd (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20120328530-A1 | TOLUIDINE BLUE DERIVATIVES AS PHOTOSENSITISING COMPOUNDS | PHARMALUCIA LIMITED (GB) | 2012-12-27 | — | — | US | disclosed |
| EP-2430007-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | Wista Laboratories Ltd. (SG) | 2012-03-21 | — | — | EP | disclosed |
| US-20120058995-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LABORATORIES LTD. (SG) | 2012-03-08 | — | — | US | disclosed |
| US-20110306576-A1 | COMPOUNDS AND METHODS RELATING THERETO | PHARMALUCIA LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| WO-2011114137-A1 | TOLUIDINE BLUE DERIVATIVES AS PHOTOSENSITISING COMPOUNDS | PHARMALUCIA LIMITED (GB) | 2011-09-22 | — | — | WO | disclosed |
| WO-2010130977-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LABORATORIES LTD. (SG) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010097626-A2 | COMPOUNDS AND METHODS RELATING THERETO | PHARMALUCIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009047534-A2 | FUSED PHENOTHIAZINIUM COMPOUNDS, PREPARATION METHOD THEREOF AND USE AS PHOTOANTIMICROBIALS | PHARMALUCIA LTD (GB) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306576-A1 | COMPOUNDS AND METHODS RELATING THERETO | QSOX1, PYM1, SQOR | S100B 3084/4885ALDH1A1 1101/4885L3MBTL1 644/4885 |
| US-20120058995-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | TST, TPMT, MGMT | S100B 962/4885ALDH1A1 748/4885L3MBTL1 4246/4885 |
| US-20120328530-A1 | TOLUIDINE BLUE DERIVATIVES AS PHOTOSENSITISING COMPOUNDS | TYR, TST, TH | S100B 1790/4885ALDH1A1 876/4885L3MBTL1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.